Phase 3 trial of fulvestrant with palbociclib for metastatic breast cancer
23rd July 2015
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Nicholas Turner, MD, PhD, of the Institute of Cancer Research and Royal Marsden Hospital, London, UK, discusses the results of the double-blind, phase 3 PALOMA3 trial of fulvestrant with or without the novel CDK 4/6-inhibitor, palbociclib, in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer who progressed on prior endocrine therapy.
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?
Keep your finger on the pulseJoin Now
Elevating the Quality of Healthcare Globally